GSK plc’s Jemperli Court Fight With AnaptysBio Takes New Turn Before July Trial
A Delaware court dismissed Tesaro’s claim that AnaptysBio anticipatorily breached their Jemperli contract, narrowing but not ending the dispute. AnaptysBio said the ruling preserves current royalty rates. GSK said the decision does not affect Tesaro’s main claim, which heads to trial in July. Jemperli generated over $1.1 billion in 2025 sales.